1-11 of 11
cytarabine
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study

Clinical Trials & Observations
Tsila Zuckerman, Ron Ram, Luiza Akria, Maya Koren-Michowitz, Ron Hoffman, Israel Henig, Noa Lavi, Yishai Ofran, Netanel A. Horowitz, Olga Nudelman, Sigal Tavor, Shay Yeganeh, Stela Gengrinovitch, Liat Flaishon, Shoshi Tessler, Ruth Ben Yakar, Jacob M. Rowe
Blood Advances (2019) 3 (22): 3740–3749.
DOI: https://doi.org/10.1182/bloodadvances.2019000468
Published: 2019
Includes: Supplemental data
Journal Articles

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Clinical Trials & Observations
Jun Yin, Betsy LaPlant, Geoffrey L. Uy, Guido Marcucci, William Blum, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar
Blood Advances (2019) 3 (11): 1714–1721.
DOI: https://doi.org/10.1182/bloodadvances.2018026112
Published: 2019
Journal Articles

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML

Clinical Trials & Observations
Renato Bassan, Tamara Intermesoli, Arianna Masciulli, Chiara Pavoni, Cristina Boschini, Giacomo Gianfaldoni, Filippo Marmont, Irene Cavattoni, Daniele Mattei, Elisabetta Terruzzi, Lorella De Paoli, Chiara Cattaneo, Erika Borlenghi, Fabio Ciceri, Massimo Bernardi, Anna M. Scattolin, Elisabetta Todisco, Leonardo Campiotti, Paolo Corradini, Agostino Cortelezzi, Dario Ferrero, Pamela Zanghì, Elena Oldani, Orietta Spinelli, Ernesta Audisio, Sergio Cortelazzo, Alberto Bosi, Brunangelo Falini, Enrico M. Pogliani, Alessandro Rambaldi
Blood Advances (2019) 3 (7): 1103–1117.
DOI: https://doi.org/10.1182/bloodadvances.2018026625
Published: 2019
Journal Articles

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia

Clinical Trials & Observations
Brian Ball, Rami S. Komrokji, Lionel Adès, Mikkael A. Sekeres, Amy E. DeZern, Lisa Pleyer, Norbert Vey, Antonio Almeida, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, Steven D. Gore, Pierre Fenaux, Thomas Prebet
Blood Advances (2018) 2 (16): 2063–2071.
DOI: https://doi.org/10.1182/bloodadvances.2018015529
Published: 2018
Includes: Supplemental data
Journal Articles

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia

Clinical Trials & Observations
Lili Aslostovar, Allison L. Boyd, Mohammed Almakadi, Tony J. Collins, Darryl P. Leong, Rommel G. Tirona, Richard B. Kim, Jim A. Julian, Anargyros Xenocostas, Brian Leber, Mark N. Levine, Ronan Foley, Mickie Bhatia
Blood Advances (2018) 2 (15): 1935–1945.
DOI: https://doi.org/10.1182/bloodadvances.2018015677
Published: 2018
Includes: Supplemental data
Journal Articles

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study

Clinical Trials & Observations
Marius Flasinski, Kira Scheibke, Martin Zimmermann, Ursula Creutzig, Katarina Reinhardt, Femke Verwer, Valerie de Haas, Vincent H. J. van der Velden, Christine von Neuhoff, C. Michel Zwaan, Dirk Reinhardt, Jan-Henning Klusmann
Blood Advances (2018) 2 (13): 1532–1540.
DOI: https://doi.org/10.1182/bloodadvances.2018018945
Published: 2018
Includes: Supplemental data
Journal Articles

Fanciullino R, Farnault L, Donnette M, et al. CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Adv . 2018;2(5):462-469.

Blood Advances (2018) 2 (9): 1013.
DOI: https://doi.org/10.1182/bloodadvances.2018019745
Published: 2018
Journal Articles

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine

Clinical Trials & Observations
Raphaelle Fanciullino, Laure Farnault, Mélanie Donnette, Diane-Charlotte Imbs, Catherine Roche, Geoffroy Venton, Yael Berda-Haddad, Vadim Ivanov, Joseph Ciccolini, L’Houcine Ouafik, Bruno Lacarelle, Regis Costello
Blood Advances (2018) 2 (5): 462–469.
DOI: https://doi.org/10.1182/bloodadvances.2017014126
Published: 2018
Journal Articles

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

Clinical Trials & Observations
Tibor J. Kovacsovics, Alice Mims, Mohamed E. Salama, Jeremy Pantin, Narayanam Rao, Ken M. Kosak, Peter Ahorukomeye, Martha J. Glenn, Michael W. N. Deininger, Kenneth M. Boucher, Linda M. Bavisotto, Gerardo Gutierrez-Sanchez, Thomas P. Kennedy, Stephen G. Marcus, Paul J. Shami
Blood Advances (2018) 2 (4): 381–389.
DOI: https://doi.org/10.1182/bloodadvances.2017013391
Published: 2018
Journal Articles

The role of targeted therapy in the management of patients with AML

Clinical Trials & Observations
Alexander E. Perl
Blood Advances (2017) 1 (24): 2281–2294.
DOI: https://doi.org/10.1182/bloodadvances.2017009829
Published: 2017
Journal Articles

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL

Clinical Trials & Observations
Farhad Ravandi, Megan Othus, Susan M. O'Brien, Stephen J. Forman, Chul S. Ha, Jeffrey Y. C. Wong, Martin S. Tallman, Elisabeth Paietta, Janis Racevskis, Geoffrey L. Uy, Mary Horowitz, Naoko Takebe, Richard Little, Uma Borate, Partow Kebriaei, Laura Kingsbury, Hagop M. Kantarjian, Jerald P. Radich, Harry P. Erba, Frederick R. Appelbaum
Blood Advances (2016) 1 (3): 250–259.
DOI: https://doi.org/10.1182/bloodadvances.2016001495
Published: 2016
Includes: Supplemental data